# NeuroXess Series B: Can Wireless Brain Implants Scale?

[Neural Tech](https://mindoxai.com/category/blog/neural-tech/)
**
Published: November 13, 2026
**
8 min read
**
[Pravesh Garcia](https://mindoxai.com/author/pravesh/)

![NeuroXess Series B: Can Wireless Brain Implants Scale?](https://d1p58i0iwq4isz.cloudfront.net/mindoxai/wp-content/uploads/2026/11/11065015/neuroxess-series-b-can-wireless-brain-implants-scale.webp)

The NeuroXess Series B raises a question that sounds simple and isn’t. Should a company build a factory for brain implants before regulators have approved a single one?
NeuroXess, a Chinese brain-computer interface (BCI) startup, raised RMB 700 million in a round reported on 28 October 2026. It plans to run a large registration trial, file for approval and get ready to manufacture at scale, all in parallel. The implant itself sits entirely under the skin and talks to the outside world wirelessly.
For the people it’s meant for, those paralyzed by complete spinal cord injury or ALS, the gap between “promising demo” and “approved device” is huge. One is a headline. The other changes a life. So it’s worth slowing down on what this money buys, and on how much of the story rests on the company’s own numbers.

## What the NeuroXess Series B actually pays for

The headline figure holds up. TechNode, RuntimeWire and 36Kr all report the same amount: RMB 700 million. [TechNode’s report](https://technode.com/2026/10/28/brain-computer-interface-startup-neuroxess-raises-rmb-700-million-in-series-b-funding/) traces it to the Chinese outlet PEdaily.
The dollar value is fuzzier. None of the reports we checked gave one. Estimates land between roughly US$98 million and US$105 million, depending on the exchange rate. We also couldn’t find an official NeuroXess press release, so every number here comes through the press.
Three firms co-led the round: SDIC Juli, Shenzhen Capital Group and Qinzhi Capital. [36Kr’s write-up](https://eu.36kr.com/de/p/4043628160685189) lists a longer tail of backers, including IDG Capital, SMIC Puyuan, Huangpu Investment and GEM Capital. It also says existing shareholders Shanda and Zhongping Capital raised their stakes. Only 36Kr names that wider group, so treat it as single-source.
The stated uses are where it gets interesting:

**Multicenter clinical trials** and the regulatory filings that follow
- **Manufacturing capacity**, which 36Kr calls a mass-production “super factory”
- **A next-generation product**
- **Research that pairs BCIs with AI**, again per 36Kr

That’s an unusual mix. You’d expect a company at this stage to pour nearly everything into getting through the clinic. This round pays for the clinic and the production line at once.

## What “fully implanted and wireless” means here

Neurosurgeon Mao Ying of Huashan Hospital didn’t hedge after the first case in late 2025. “We implanted China’s first fully implanted, wireless, battery-powered BCI system,” he told [China Daily](https://www.chinadaily.com.cn/a/202512/11/WS693a2979a310d6866eb2e135.html).

Going by that report, the hardware breaks down like this:
- A **coin-shaped implant** sits in a thinned recess of the skull, above the motor cortex, the strip of brain that controls movement.
- **Ultra-flexible electrodes** pick up signals from that region.
- A **wearable cap** carries the external receivers for wireless power and signals.

The appeal is easy to see. Nothing crosses the skin, so there’s no open port to keep clean and no cable tethering the patient to a cart.

Now the caveat. Some secondary coverage describes a different layout, with a processor and battery tucked under the skin of the chest. We couldn’t verify that, and it clashes with China Daily’s account, so we’re going with the skull-recess version. We also don’t know whether the implant from that 2025 case is the same design now in trial. No source we checked says so.

## The Huashan case behind the funding

The first patient was a 28-year-old man who had lived with paralysis for eight years. Surgeons at Huashan Hospital implanted the system in late October 2025. China Daily reported three results:
- He controlled a cursor **five days** after initial training.
- By **day 17**, his performance matched Neuralink’s benchmark in tests.
- He went on to operate smart-home systems and humanoid robots.

That’s one person, described by state media. It’s encouraging, and it’s thin. A single case can show a device works in a human brain. It can’t tell you how often it fails, how long the electrodes keep a clean signal, or what year three looks like.

Founder Tao Hu frames the goal in plainly human terms. In 36Kr’s coverage, he says he hopes the system can give patients back their dignity. That’s the right goal. It’s also exactly why the evidence has to be solid.

## Why the registration trial matters more than the money

In July 2026, NeuroXess began a Class III medical device registration trial run under GCP (good clinical practice) rules. According to 36Kr, Huashan Hospital, part of Fudan University, leads it, with Prof. Mao Ying as principal investigator. Nearly 20 hospitals take part.

If you keep one idea from this post, keep this distinction:
- An **early feasibility study** asks whether a device is safe enough to keep testing, usually in a handful of people.
- A **registration trial** produces the evidence regulators use to decide on approval. Class III is the highest-risk device tier, so the bar sits high.

Put simply, this is the trial that’s supposed to end in a yes or a no. Everything the NeuroXess Series B pays for downstream depends on it.

The reports also say NeuroXess has completed 65 clinical cases. Handle that number with care, along with “nearly 20 hospitals.” Both come from the company. TechNode and 36Kr relay them, and the two outlets appear to draw on the same Chinese source. Nobody has audited them, and nobody has said what counts as a “case.”

### Not every Huashan brain implant belongs to NeuroXess

One more trap. Huashan hosts more than one wireless BCI study. Take the recruiting trial listed as NCT07603752, an implantable wireless brain-machine interface for spinal cord injury. It started on 28 April 2026, and a different company, Shanghai StairMed, sponsors it. If a story about the NeuroXess Series B quotes Huashan trial details, check whose trial it’s actually describing.

## Why a 10,000-system factory is a bet

TechNode reports a 14,300-square-meter plant with planned capacity of 10,000 systems a year. TechNode says it’s under construction; RuntimeWire calls it planned. The wording gap matters less than the logic.

RuntimeWire points out that the production plans hinge on how the registration trial turns out. A plant sized for 10,000 implants a year only pays off if regulators approve the device and patients can actually get it. If the trial disappoints, that’s an expensive empty building.

So why build early? Our read: capacity on hand shortens the wait between approval and availability. Patients wouldn’t sit idle while the company scrambles to set up a production line after the green light. That’s a confident move, and the factory is the boldest line item in the NeuroXess Series B. It also tells investors, loudly, that the company expects to win.

## China’s BCI push vs the US approach

China Daily describes China as the second country, after the US, to take invasive BCIs into clinical trials. The same report projects approval for the NeuroXess device by 2028, for patients with complete spinal cord injury or ALS.

Read 2028 as a projection, not a promise. It rests on a trial that only began in July 2026.

The more useful contrast isn’t who’s “ahead.” It’s sequencing. Neuralink, Synchron and Paradromics get most of the Western headlines, and we’ve compared their approaches in [Neuralink vs Synchron vs Paradromics: The Brain-Chip Race, Compared](https://mindoxai.com/blog/neural-tech/neuralink-vs-synchron-vs-paradromics/). The NeuroXess Series B funds clinical validation and industrial capacity side by side, which is how RuntimeWire frames it too.

Is that smarter or just riskier? Honestly, both. We looked at an earlier Chinese world-first claim in [China’s Brain-Computer Chip: World-First, But Is It Safe?](https://mindoxai.com/blog/neural-tech/china-brain-computer-chip-safe/), and the same instinct applies. Firsts are easy to announce and hard to compare.

## What’s still unproven

The NeuroXess Series B buys time and capacity. It doesn’t buy answers to these:
- **Independent data.** The 65 cases and the hospital count come from the company. Peer-reviewed registration-trial results would change the conversation.
- **Design continuity.** We don’t know if the implant from the 2025 Huashan case is the one under trial now.
- **Long-term performance.** A day-17 benchmark says nothing about year five.
- **Access and cost.** None of the reports we checked mentions a price. A device only some patients can afford raises the questions in [Will Brain Chips Deepen the Human Class Divide?](https://mindoxai.com/blog/cognitive-augmentation/will-brain-chips-deepen-the-human-class-divide/)
- **Neural data.** This implant beams brain signals to an external receiver. Who stores that data, and who can demand it, is the problem we dug into in [Neuroprivacy: What Governments Can Really Subpoena](https://mindoxai.com/blog/neural-tech/neuroprivacy-what-governments-can-really-subpoena/).

## The money is real. The evidence isn’t in yet.

The RMB 700 million is real. The factory is real, or close to it. What doesn’t exist yet is the thing that would justify both: a finished registration trial, reported in a way outsiders can check.

If NeuroXess delivers that, the 10,000-unit plant will look like foresight, and this round will read as the one that got Chinese BCIs to patients faster. If it doesn’t, people will remember it as the moment the industry got ahead of its own data. We’d rather wait for the trial readout before picking a side.

What would you need to see before you’d trust a wireless implant inside your own skull?

Author & Contributor

### Pravesh Garcia

Writes explainers and analysis for Mindox AI on AGI, artificial intelligence, neural technology and cognitive augmentation. Articles are based on primary sources such as research papers, company releases and regulatory documents, and follow the [Editorial Policy](https://mindoxai.com/editorial-policy/).

[Follow](https://mindoxai.com/author/pravesh/)

## Frequently Asked Questions

**Q:** What is NeuroXess and what does it do?

**A:** NeuroXess is a Chinese brain-computer interface company. It develops an implant that sits fully under the skin and communicates wirelessly, aimed at people with paralysis from conditions such as complete spinal cord injury or ALS. Its founder and chief scientist is Tao Hu.

**Q:** How much did NeuroXess raise and who invested?

**A:** NeuroXess raised RMB 700 million in a Series B reported on 28 October 2026. SDIC Juli, Shenzhen Capital Group and Qinzhi Capital co-led the round. 36Kr also lists IDG Capital, SMIC Puyuan, Huangpu Investment, GEM Capital and others, with existing shareholders Shanda and Zhongping Capital increasing their stakes. No official dollar figure was published; estimates range from about US$98 million to US$105 million depending on the exchange rate.

**Q:** What does a fully implanted wireless brain-computer interface mean?

**A:** It means no wire or connector crosses the skin. In the case China Daily described, a coin-shaped implant with ultra-flexible electrodes sits in a thinned recess of the skull above the motor cortex, while a wearable cap holds the external receivers for wireless power and signals.

**Q:** How does NeuroXess compare with Neuralink and Synchron?

**A:** There is no head-to-head data. China Daily reported that NeuroXess's first patient matched Neuralink's benchmark in tests by day 17 after training began. That is one patient in one report, so it is not a meaningful ranking. We found no published comparison with Synchron.

**Q:** What is a BCI registration trial and why does it matter?

**A:** A registration trial produces the evidence regulators use to decide whether to approve a device. NeuroXess began a Class III medical device registration trial in July 2026, led by Huashan Hospital of Fudan University with nearly 20 hospitals taking part. Its outcome, not the funding, will decide whether the implant reaches patients.

**Q:** When could NeuroXess's system reach patients?

**A:** China Daily projected regulatory approval by 2028 for patients with complete spinal cord injury or ALS. Treat that as a projection: it depends on a registration trial that only began in July 2026.

**Q:** Is China ahead of the US in brain-computer interfaces?

**A:** Not clearly. China Daily describes China as the second country after the US to take invasive BCIs into clinical trials. What stands out about China's approach, as seen in this round, is funding clinical trials and manufacturing capacity at the same time.